Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-25864-0 |
| _version_ | 1818754280145813504 |
|---|---|
| author | Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng |
| author_facet | Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng |
| author_sort | Yi-Sheng Chang |
| collection | DOAJ |
| description | Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome. |
| first_indexed | 2024-12-18T05:20:44Z |
| format | Article |
| id | doaj.art-bf60fbae34e04c8eb45e500e819ecf7d |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-18T05:20:44Z |
| publishDate | 2018-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-bf60fbae34e04c8eb45e500e819ecf7d2022-12-21T21:19:40ZengNature PortfolioScientific Reports2045-23222018-05-018111110.1038/s41598-018-25864-0Real-world use of ranibizumab for neovascular age-related macular degeneration in TaiwanYi-Sheng Chang0Wan-Ju Lee1Chen-Chee Lim2Shih-Hao Wang3Sheng-Min Hsu4Yi-Chian Chen5Chia-Yi Cheng6Yu-Ti Teng7Yi-Hsun Huang8Chun-Chieh Lai9Sung-Huei Tseng10Department of Ophthalmology, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityDepartment of Ophthalmology, College of Medicine, National Cheng Kung UniversityAbstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.https://doi.org/10.1038/s41598-018-25864-0 |
| spellingShingle | Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan Scientific Reports |
| title | Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan |
| title_full | Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan |
| title_fullStr | Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan |
| title_full_unstemmed | Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan |
| title_short | Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan |
| title_sort | real world use of ranibizumab for neovascular age related macular degeneration in taiwan |
| url | https://doi.org/10.1038/s41598-018-25864-0 |
| work_keys_str_mv | AT yishengchang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT wanjulee realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chencheelim realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT shihhaowang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT shengminhsu realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yichianchen realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chiayicheng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yutiteng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yihsunhuang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chunchiehlai realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT sunghueitseng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan |